CoChat

A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia

Open access
El-Maouche, Diala, Merke, Deborah P, Vogiatzi, Maria G, Chang, Alice Y, Turcu, Adina F, Joyal, Elizabeth G, Lin, Vivian H, Weintraub, Lauren, Plaunt, Marianne R, Mohideen, Pharis, Auchus, Richard J · 2020 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.

Abstract

Context: Patients with classic congenital adrenal hyperplasia (CAH) often require supraphysiologic glucocorticoid doses to suppress adrenocorticotropic hormone (ACTH) and control androgen excess. Nevanimibe hydrochloride (ATR-101), which selectively inhibits adrenal cortex function, might reduce androgen excess independent of ACTH and thus allow for lower glucocorticoid dosing in CAH. 17-hydroxyprogesterone (17-OHP) and androstenedione are CAH biomarkers used to monitor androgen excess. Objective: Evaluate the efficacy and safety of nevanimibe in subjects with uncontrolled classic CAH. Design: This was a multicenter, single-blind, dose-titration study. CAH subjects with baseline 17-OHP ≥4× the upper limit of normal (ULN) received the lowest dose of nevanimibe for 2 weeks followed by a single-blind 2-week placebo washout. Nevanimibe was gradually titrated up if the primary outcome measure (17-OHP ≤2× ULN) was not met. A total of 5 nevanimibe dose levels were possible (125, 250, 500, 750, 1000 mg twice daily). Results: The study enrolled 10 adults: 9 completed the study, and 1 discontinued early due to a related serious adverse event. At baseline, the mean age was 30.3 ± 13.8 years, and the maintenance glucocorticoid dose, expressed as hydrocortisone equivalents, was 24.7 ± 10.4 mg/day. Two subjects met the primary endpoint, and 5 others experienced 17-OHP decreases ranging from 27% to 72% during nevanimibe treatment. The most common side effects were gastrointestinal (30%). There were no dose-related trends in adverse events. Conclusions: Nevanimibe decreased 17-OHP levels within 2 weeks of treatment. Larger studies of longer duration are needed to further evaluate its efficacy as add-on therapy for CAH.

Overview

Integrity signals

Registry

Crossref · 10.1210/clinem/dgaa381

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Cited by

See all 35

Metadata

Authors
El-Maouche, D., Merke, D. P., Vogiatzi, M. G., Chang, A. Y., Turcu, A. F., Joyal, E. G., Lin, V. H., Weintraub, L., Plaunt, M. R., Mohideen, P., & Auchus, R. J.
Affiliations
  • Division of Endocrinology & Metabolism, George Washington University, Washington, DC
  • National Institutes of Health (US)
  • Division of Endocrinology and Diabetes, Children’s Hospital of Pennsylvania, Philadelphia, Pennsylvania
  • Mayo Clinic (US)
  • University of Michigan (US)
  • Millendo Therapeutics (United States) (US)
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2020-06-26
Volume
105
Issue
8
Pages
2771-2778
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W3037125154
Cited by
34
References
22
Citations by year
2026: 7 · 2025: 2 · 2024: 4 · 2023: 4 · 2022: 9 · 2021: 5 · 2020: 3
FWCI
1.70
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, public-domain)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
Keywords
congenital adrenal hyperplasia, 17-hydroxyprogesterone, hyperandrogenism, glucocorticoid dose reduction, dose titration, adverse events, adults
MeSH terms
Administration, Oral, Adolescent, Adrenal Cortex, Adrenal Hyperplasia, Congenital, Adrenocorticotropic Hormone, Adult, Androstenedione, Dose-Response Relationship, Drug, Drug Therapy, Combination, Glucocorticoids, Humans, Middle Aged, Urea, Biomarkers, Treatment Outcome, Cross-Over Studies, 17-alpha-Hydroxyprogesterone, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia. https://app.cochat.ai/papers/10.1210/clinem/dgaa381
The paper
El-Maouche, D., Merke, D. P., Vogiatzi, M. G., Chang, A. Y., Turcu, A. F., Joyal, E. G., Lin, V. H., Weintraub, L., Plaunt, M. R., Mohideen, P., & Auchus, R. J. (2020). A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaa381

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.